SAN FRANCISCO--(BUSINESS WIRE)--Trilobio, developer of whole lab automation solutions for advancing biology research, today introduced the first version of its comprehensive robotics, lab equipment ...

Labroots is delighted to host the 9th Annual Event in the Laboratory Automation Virtual Event Series, scheduled on March 19th, 2025! Dive into the cutting edge of laboratory technology at this free ...

Artificial intelligence (AI) and laboratory automation have already shown promise for revolutionizing research in biotechnology. These technologies offer tremendous opportunities to be leveraged for ...

Biosero, a BICO company and developer of integrated laboratory automation solutions, signed a master service agreement with a global pharma company in August 2025 and has now received the first ...

Ginkgo will build a platform driven by its Reconfigurable Automation Carts (RACs) technology to enable EMSL's open-ended exploration of bioconomy-relevant microbes Under this $4.66M contract, Ginkgo ...

Researchers in the the labs of Ron Alterovitz, a Lawrence Grossberg Distinguished Professor in the Department of Computer Science, and Jim Cahoon, a professor and chair of the Department of Chemistry, ...

Automation of repetitive tasks has long been one of the main pillars of industry. The increase in computational resources, machine learning, and robotic hardware in the last decades has now allowed to ...

For the past couple of years, innovation has been accelerating in new materials development. And a new French startup called Altrove plans to play a role in this innovation cycle. The deep tech ...

The progress in laboratory automation could be one of the most consistent changes in research in the life sciences and biomedicine over the past 30 years. The evolution of this field borders on the ...

The complexity of antibody-drug conjugates (ADCs) demands equally sophisticated analytical strategies. Researchers must navigate fragmented workflows, manual sample preparation, and experimental ...

Conventional treatment options for patients diagnosed with solid cancers or autoimmune diseases are often limited or ineffective. Developing alternative treatments for these challenging conditions ...